CSIMarket
 


Axim Biotechnologies Inc   (AXIM)
Other Ticker:  
 

Cumulative Axim Biotechnologies Inc 's Working Capital Ratio for Trailing Twelve Months Period

AXIM's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

AXIM Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 35.25 % 208.52 % 44.69 % 29.59 % 98.33 %
Y / Y Current Assets Growth -87.32 % -40.22 % -89.11 % -83.67 % -49.16 %
Working Capital Ratio for Trailing Twelve Months Period 0.01 0.03 0.04 0.09 0.14
Total Ranking # 3989 # 4200 # 4352 # 4918 # 4647
Seq. Current Liabilities Growth -48.86 % 72.01 % 45.4 % 5.74 % 16.66 %
Seq. Current Assets Growth -69.74 % 81.94 % -43.7 % -59.1 % 42.68 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to drop in Current Liabilities in the III. Quarter to $4 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 0.01 below Axim Biotechnologies Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 497 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Axim Biotechnologies Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about AXIM
Working Capital Ratio AXIM in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 498
Sector # 1038
S&P 500 # 3992


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
0.7 0.33 0.01
(Sep 30 2019)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Actavia Life Sciences Inc   0.04 
Innovation1 Biotech Inc   0.03 
Cen Biotech Inc  0.03 
Biostax Corp  0.03 
Regen Biopharma Inc  0.03 
Axim Biotechnologies Inc   0.03 
Theralink Technologies Inc   0.02 
Propanc Biopharma Inc   0.02 
Nanomix Corp  0.02 
Oncotelic Therapeutics Inc   0.02 
Skinvisible Inc   0.02 
Q Biomed inc   0.02 
Novaccess Global Inc   0.02 
Kaya Holdings Inc  0.01 
Rebus Holdings Inc   0.01 
Viveon Health Acquisition Corp   0.01 
Adhera Therapeutics Inc   0.01 
Respirerx Pharmaceuticals Inc   0.01 
Hst Global Inc 0.00 
Globestar Therapeutics Corporation 0.00 
Cannapharmarx Inc 0.00 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com